Research programme: carbon monoxide releasing molecules - Proterris

Drug Profile

Research programme: carbon monoxide releasing molecules - Proterris

Alternative Names: ALF 421; CORM-A1; CORMs - Proterris

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALFAMA
  • Developer Proterris
  • Class Aldehydes; Carbonates; Organometallic compounds; Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Liver failure; Non-alcoholic steatohepatitis
  • No development reported Inflammation; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Portugal
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Portugal
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Portugal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top